News
NKTR
0.9078
+0.81%
0.0073
Weekly Report: what happened at NKTR last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at NKTR last week (1209-1213)?
Weekly Report · 12/16 09:25
Promising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment with Rezpegaldesleukin
TipRanks · 12/12 07:45
Nektar initiated with a Buy at H.C. Wainwright
TipRanks · 12/10 11:10
NEKTAR THERAPEUTICS <NKTR.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $6.5
Reuters · 12/10 11:06
Weekly Report: what happened at NKTR last week (1202-1206)?
Weekly Report · 12/09 09:24
Nektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell Lymphoma
NASDAQ · 12/08 01:51
Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group Achieved Complete Response At 6 Months
Benzinga · 12/07 20:28
NEKTAR THERAPEUTICS ANNOUNCES NKTR-255 FOLLOWING CD19-DIRECTED CAR-T THERAPY ENHANCED COMPLETE RESPONSE RATES IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA AT THE 66TH ANNUAL ASH MEETING
Reuters · 12/07 17:00
Nektar Therapeutics To Present At Piper Sandler Healthcare Conference; Webcast At 1:00 PM ET
NASDAQ · 12/04 17:04
Weekly Report: what happened at NKTR last week (1125-1129)?
Weekly Report · 12/02 09:24
Weekly Report: what happened at NKTR last week (1118-1122)?
Weekly Report · 11/25 09:22
Insider Sale: Chief R&D Officer of $NKTR (NKTR) Sells 7,785 Shares
Barchart · 11/21 05:52
Nektar presents preclinical data on NKTR-422 at ACR conference
TipRanks · 11/18 20:50
Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflammatory Conditions
Benzinga · 11/18 20:32
Weekly Report: what happened at NKTR last week (1111-1115)?
Weekly Report · 11/18 09:22
Multiple Catalysts Ahead For Nektar Therapeutics
Seeking Alpha · 11/14 14:11
Nektar Therapeutics To Present At UBS Global Healthcare Conference; Webcast At 1:15 PM ET
NASDAQ · 11/13 17:18
Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
TipRanks · 11/12 12:48
Weekly Report: what happened at NKTR last week (1104-1108)?
Weekly Report · 11/11 09:24
More
Webull provides a variety of real-time NKTR stock news. You can receive the latest news about Nektar Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.